AstraZeneca
2025.04.30
13:00
AstraZeneca responds to latest fine in China
AstraZeneca responded to the latest fines it may face in China, saying: "The "Identification Opinion Notice" issued by the Shenzhen Customs Anti-Smuggling Bureau shows that the company is suspected of evading import taxes, amounting to more than 1.6 million US dollars." According to relevant information, AstraZeneca believes that the import taxes mentioned in the "Identification Opinion Notice" involve Enhertu. If AstraZeneca is ultimately found to be legally responsible, it may be fined one to five times the unpaid import taxes, with a maximum amount of up to 8 million US dollars.
2025.04.29
14:54
AstraZeneca (AZN.O) CEO: The impact of US tariffs on AstraZeneca will be short-lived.
2025.04.23
19:06
AstraZeneca (AZN.O) CEO: Europe is falling behind in attracting investment in pharmaceutical research and development and manufacturing.
19:04
AstraZeneca (AZN.O) CEO: Europe has increased defense spending and now must protect its medical sovereignty.
2025.04.22
15:10
AstraZeneca: Viagra approved in China for the treatment of adult patients with generalized myasthenia gravis
On April 22, AstraZeneca announced that the long-acting C5 complement inhibitor Ultomiris (English trade name: Ultomiris, generic name: reslizumab injection) was officially approved in China for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients with positive anti-acetylcholine receptor (AChR) antibodies. Currently, reslizumab has been approved for the treatment of adult gMG patients with positive anti-AChR antibodies in the United States, the European Union, Japan and other countries and regions, and has been approved for multiple indications in many countries and regions around the world.
14:42
AstraZeneca's new myasthenia gravis antibody drug approved in China, to be administered once every 8 weeks
On April 22, AstraZeneca announced that the marketing application for ravulizumab injection has been approved by the China National Medical Products Administration (NMPA) for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) antibodies. Ravulizumab is a long-acting complement C5 protein inhibitor that is administered once every 8 weeks.
12:20
AstraZeneca: Trancocort combined with Fulvestrant approved in China for patients with HR-positive advanced breast cancer
On April 22, AstraZeneca announced that the China National Medical Products Administration officially approved Capisetid (generic name: Capisetid tablets) combined with Fulvestrant on April 15, 2025 for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy in the metastatic stage, or relapsed during adjuvant therapy or within 12 months after completion of adjuvant therapy, who are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and have one or more PIK3CA/AKT1/PTEN changes.
12:12
The National Medical Products Administration approved the first AKT inhibitor for marketing
AstraZeneca announced that the China National Medical Products Administration has officially approved Truqap (English trade name: Truqap, generic name: Capisetib tablets) combined with Fulvestrant for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy in the metastatic stage, or who have relapsed during adjuvant therapy or within 12 months after completing adjuvant therapy, and who are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and have one or more PIK3CA/AKT1/PTEN changes.
2025.04.09
15:04
Shares of London-listed pharmaceutical companies fell, with AstraZeneca falling 4.5% and GlaxoSmithKline falling 3.2%.
2025.04.03
21:30
U.S. stock market opens: three major indexes open sharply lower
The US tariff measures triggered panic in the market. The three major US stock indexes opened sharply lower, with the Dow Jones Industrial Average down 3%, the S&P 500 down 3.41%, and the Nasdaq down 4.6%. Large technology stocks led the decline, with Apple falling 8%, Broadcom, Amazon, Tesla, and Nvidia down more than 6%, and Microsoft down nearly 2%. AstraZeneca rose more than 4%, claiming that oral lipid-lowering drugs can reduce "bad cholesterol" by more than 50%.
2025.03.23
23:00
AstraZeneca Global CEO: Delivering "Made-in-China" drugs to more than 70 countries and regions around the world
AstraZeneca's global CEO Soriot said that China's supply chain is an important and stable pillar of AstraZeneca's global business. Relying on its high quality, high cost-effectiveness and efficient production capacity, we deliver Chinese-made medicines to more than 70 countries and regions around the world. On the same day, the China Development Forum 2025 Annual Meeting was held in Beijing. Soriot said during the forum that the importance of China's continued opening up is self-evident. The core lies in cooperation. Cooperation is the key to the successful development of new drugs. China's open environment will give rise to more cooperation opportunities.
08:16
Beijing Mayor Yin Yong meets with AstraZeneca's global CEO
On the afternoon of March 21, Beijing Mayor Yin Yong met with AstraZeneca's global CEO Soriot. Yin Yong said that with the further comprehensive deepening of reform and expansion of opening up, more pilot and open policies in the pharmaceutical field will be implemented in Beijing faster. We hope that AstraZeneca will make good use of Beijing's advantages, expand its R&D and investment layout in Beijing, promote more R&D pipelines to conduct clinical trials in Beijing, and help Beijing's pharmaceutical and health industry develop with high quality. Soriot said that China is gradually becoming an important source of global scientific and technological innovation. We are willing to further cultivate the Chinese market, take root in Beijing's development, make good use of Beijing's scientific and technological innovation resources, accelerate the implementation of drug R&D and clinical application cooperation in Beijing, achieve better cooperation and win-win results for both sides, and benefit more patients.
2025.03.21
19:09
AstraZeneca announces $2.5 billion investment to establish global strategic R&D center in Beijing
AstraZeneca announced on March 21 that it would invest $2.5 billion to establish its sixth global strategic research and development center in Beijing. The investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Committee, and includes agreements signed with three biotechnology companies (Harbour Biopharma, Syneron Bio and Kangtai Biological).
2025.03.17
15:39
AstraZeneca to buy Belgian biotech EsoBiotec for up to $1 billion
On March 17, AstraZeneca announced that it had agreed to acquire Belgian biotechnology company EsoBiotec for a total price of up to US$1 billion.
2025.03.03
14:00
Goldman Sachs has included AstraZeneca, Novo Nordisk and Rio Tinto on its European "confidence list".
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.

2025-05-02

US judge rules Apple violated order to reform App Store

2025-05-01

Shanghai: Using tax support to encourage more innovation and help companies go global

2025-04-30

Ideal Auto's Ring OS is officially open source, and the code is now available for download

2025-04-28

Apple (AAPL.O) had a net profit of US$24.78 billion in the second quarter of fiscal year 2025, compared with market expectations of US$24.26 billion and US$23.636 billion in the same period last year.

2025-05-02

ASIA TECH WIRE

Grasp technology trends

Download